Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 19/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294818 | 1.00 | SORD (0.64) | SORD | |
| SCHEMBL6822451 | 0.83 | SORD (0.64) | SORD | |
| SCHEMBL6293136 | 0.83 | SORD (0.64) | SORD | |
| SCHEMBL6294659 | 0.82 | SORD (0.61) | SORD | |
| SCHEMBL6822488 | 0.82 | SORD (0.61) | SORD | |
| SCHEMBL6293110 | 0.81 | SORD (0.55) | SORD | |
| SCHEMBL7190884 | 0.81 | SORD (0.55) | SORD | |
| SCHEMBL6293234 | 0.80 | SORD (0.52) | SORD | |
| SCHEMBL6822500 | 0.80 | SORD (0.52) | SORD | |
| SCHEMBL6297864 | 0.78 | SORD (1.00) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337271-B1 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| EP-1337271-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| EP-1326591-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002098429-A1 | ETHANOLAMINE, DIETHANOLAMINE OR TRIETHANOLAMINE SALT OF ZOPOLRESTAT | PFIZER PRODUCTS INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | MYLARI BANAVARA L (US) | 2002-07-11 | — | — | US | claimed |
| WO-2002043762-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2002032411-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
| EP-1337271-B1 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1337271-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1326591-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002098429-A1 | ETHANOLAMINE, DIETHANOLAMINE OR TRIETHANOLAMINE SALT OF ZOPOLRESTAT | PFIZER PRODUCTS INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002043762-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002032411-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | SORD, GABRE, SLC6A1 | SORD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.